(-)-frenolicin | 10023-07-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并吡喃类
• 英文名称: (-)-frenolicin
• 英文别名: Frenolicin；2-[(1S,10R,11R,13S)-7-hydroxy-2,9-dioxo-11-propyl-12,15-dioxatetracyclo[8.4.1.01,10.03,8]pentadeca-3(8),4,6-trien-13-yl]acetic acid
• CAS: 10023-07-1
• 化学式: C₁₈H₁₈O₇
• 分子量: 346.337
• InChiKey: RJPAAOHQLUUTRQ-KSVPUCKHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (-)-frenolicin 在 氢溴酸 作用下， 以 溶剂黄146 为溶剂， 反应 14.0h， 以6.4 mg的产率得到3-溴噻吩
  参考文献：
  名称：

  Synthesis of racemic frenolicin via organochromium and organopalladium intermediates

  摘要：

  DOI：

  10.1021/ja00345a061
• 作为产物：
  描述：

  frenolicin F 在 戴斯-马丁氧化剂 作用下， 以 氘代氯仿 为溶剂， 反应 0.17h， 生成 (-)-frenolicin
  参考文献：
  名称：

  Frenolicins C-G，来自链霉菌属的吡喃萘醌。RM-4-15

  摘要：

  选择阿巴拉契亚活跃的煤火点来分离属于放线菌类的细菌菌株。从分离提取物到天然产物数据库的高分辨率电喷雾电离质谱 (HRESIMS) 和紫外 (UV) 吸收谱的比较表明链霉菌属。RM-4-15 产生独特的代谢物。从该菌株的发酵中分离出四种新的吡喃萘醌类化合物富伦菌素 C–F ( 1 – 4 ) 以及三种已知的类似物富伦菌素 ( 6 )、富伦菌素 B ( 7 ) 和 UCF76-A ( 8 )。另一种新类似物富伦菌素 G ( 5 ) 以及两种已知化合物脱氧富伦菌素 (9 ) 和 UCF 13 ( 10 )，是从提供 18mg/L 氯化钪的发酵中分离出来的，第一个例子，据我们所知，其中氯化钪补充导致新细菌次级代谢产物的确认产生。结构1 - 5分别鉴定光谱分析和化学改性的基础上。而富伦霉素是最适合他们的抗球虫活性已知的，目前的研究显示化合物6 - 9显示出对人肺癌细胞系（A549）中等细胞毒性，并由此延伸，用于这个特权支架抗癌SAR。

  DOI：

  10.1021/np400231r

文献信息

• [EN] FAP-TARGETED RADIOPHARMACEUTICALS AND IMAGING AGENTS, AND USES RELATED THERETO<br/>[FR] AGENTS D'IMAGERIE ET PRODUITS RADIOPHARMACEUTIQUES CIBLANT LA FAP, ET UTILISATIONS ASSOCIÉES
  申请人：TUFTS COLLEGE

  公开号：WO2021195198A1

  公开（公告）日：2021-09-30

  The tumor stroma, which accounts for a large part of the tumor mass, represents an attractive target for the delivery of diagnostic and therapeutic compounds. Here, the focus is notably on a subpopulation of stromal cells, known as cancer-associated fibroblasts, which are present in more than 90% of epithelial carcinomas, including pancreatic, colon, and breast cancer. Cancer-associated fibroblasts feature high expression of TAP, which is not detectable in adult normal tissue but is associated with a poor prognosis in cancer patients. The present invention provides small-molecule radiopharmaceutical and imaging agents based on a FAP-specific inhibitor.

  肿瘤基质占据肿瘤质量的很大一部分，是传递诊断和治疗化合物的一个有吸引力的靶点。在这里，重点特别放在一种称为癌相关成纤维细胞的基质细胞亚群上，这种细胞存在于超过90%的上皮癌中，包括胰腺癌、结肠癌和乳腺癌。癌相关成纤维细胞具有高表达TAP的特征，在成人正常组织中无法检测到，但与癌症患者的不良预后相关。本发明提供基于FAP特异性抑制剂的小分子放射性药物和成像剂。
• PYRANONAPHTHOQUINONE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：University of Kentucky Research Foundation

  公开号：US20180055816A1

  公开（公告）日：2018-03-01

  Provided herein are pyranonaphthoquinone compounds and methods of using pyranonaphthoquinone compounds. The method of using the pyranonaphthoquinone compounds includes selectively inhibiting 4E-BP1 phosphorylation by administering at least one pyranonaphthoquinone or pyranonaphthoquinone analog to a subject in need thereof. The pyranonaphthoquinone compounds includes a structure according to Formula I:

  本文提供了吡喃萘醌化合物以及使用吡喃萘醌化合物的方法。使用吡喃萘醌化合物的方法包括通过向需要的受试者施用至少一种吡喃萘醌或吡喃萘醌类似物来选择性地抑制4E-BP1的磷酸化。吡喃萘醌化合物包括符合以下式I的结构：
• NOVEL TACROLIMUS ANALOGUES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME
  申请人：EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION

  公开号：US20130230559A1

  公开（公告）日：2013-09-05

  The present invention relates to novel tacrolimus analogues, a composition for the prevention or treatment of neurological diseases or immune hypersensitivity disorders comprising the same, a method for preventing or treating neurological diseases or immune hypersensitivity disorders comprising administering the analogues to a subject, a method for preparing the analogues using an isolated modified Streptomyces sp. strain wherein the activity of one or more enzymes selected from the group consisting of TcsA, TcsB, TcsC and TcsD is reduced; and the isolated modified Streptomyces sp. strain for prepare the analogues.

  本发明涉及新型他克莫司类似物，一种用于预防或治疗神经疾病或免疫过敏性疾病的组合物，包括相同的组成部分，一种通过向受试者施用类似物来预防或治疗神经疾病或免疫过敏性疾病的方法，一种使用经过改良的分离链霉菌菌株制备类似物的方法，其中来自于TcsA、TcsB、TcsC和TcsD组中选择的一个或多个酶的活性被降低；以及用于制备类似物的经过改良的分离链霉菌菌株。
• Preparation of prodrugs for selective drug delivery
  申请人：Mills L. Randell

  公开号：US20050080260A1

  公开（公告）日：2005-04-14

  Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

  合成具有A-B-C化学式的化合物，可用于药物传递等应用，其中A是化学发光基团，B是光致变色基团，C是生物活性基团，其中A-B-C可作为前药。本发明的新型合成方法用于形成前药，包括以下步骤：(1)形成苯酮，(2)形成二芳基乙烯，(3)将邻苯二甲酰亚胺基团连接到乙烯的至少一个芳基上，形成邻苯二甲酰亚胺-乙烯共轭物，(4)缩合两个乙烯-邻苯二甲酰亚胺共轭物，形成邻苯二甲酰亚胺-戊二烯共轭物，(5)通过与肼反应将邻苯二甲酰亚胺转化为邻苯二酰肼，形成本发明的载体化合物，(6)将载体化合物与药物的亲核基团反应，形成相应的前药。另外，可以通过使用卤代二芳基乙烯制备相应的阳离子类似的类似类似染料化合物。然后，通过与亲核试剂反应保护阳离子类似化合物，并通过钯催化的胺化与氨基邻苯二甲酰亚胺偶联，形成保护的邻苯二甲酰亚胺-戊二烯共轭物。后者与肼回流，将其邻苯二甲酰亚胺转化为邻苯二酰肼，并酸化以得到载体。本发明的另一个方面涉及将这些化合物用作抗病毒剂，用于治疗病毒感染，如HIV，以及用作抗癌剂，用于治疗结肠癌、肺癌和乳腺癌等癌症。
• Carriers, Formulations, Methods For Formulating Unstable Active Agents For External Application And Uses Thereof
  申请人：Foamix Ltd.

  公开号：US20130189191A1

  公开（公告）日：2013-07-25

  The present disclosure teaches unique formulations for topical administration of tetracycline antibiotics, in which the tetracycline antibiotics remain stable.

  本公开教授了一种独特的四环素类抗生素外用给药配方，其中四环素类抗生素保持稳定。